Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum

NCT07271199 | Active Not Recruiting

• 1 other identifier: 25-089-A
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin. A total of 30 healthy female participants, aged 18 to 60, will be recruited and randomly assigned to two groups receiving different serum formulations. Participants will apply the product twice daily for 112 days (16 weeks), with eyelash and periorbital skin conditions assessed at multiple time points using non-invasive measurements. Key parameters include eyelash density, eyelash length, and overall periorbital skin condition. At the end of the study (Day 112), both participant self-assessments and evaluations by an eyelash specialist will be conducted to assess changes in eyelash and skin condition.

Conditions

Skin Condition; Eyelash Growth; Eyelashes; Skin Health; Hair Health

Keywords

Eyelash; Eyelash health; Skin health; Eyelash condition; Hair health; Product formulation; Growth factors; Extracellular vesicle; Ginger; Turmeric

Outcome Measures

Primary Outcomes (3)

• Eyelash density

  Assess eyelash density with Canfield VISIA® Skin Analysis system by assigning score from 1 (most dense, thick eyelashes) to 5 (least dense, thin eyelashes). Results will be expressed as percentage of change in eyelash density percentage relative to Day 0.

  Assessment conducted every 28 days from Day 0 to Day 112 (including Day 0 as baseline)

• Eyelash length

  Assess eyelash length with Canfield VISIA® Skin Analysis system by assigning score from 1 (longest eyelashes) to 5 (shortest eyelashes). Results will be expressed as percentage of change in eyelash length percentage relative to Day 0

  Assessment conducted every 28 days from Day 0 to Day 112 (including Day 0 as baseline)

• Periorbital skin and eye conditional questionnaire

  Participants will be asked to answer a questionnaire for self-assessment of periorbital skin conditions such as swelling, irritation, pigmentation, redness, and allergic reaction; corneal and retinal conditions including swelling, hyperemia, and allergic reaction will also be self-evaluated.

  Assessment conducted every 28 days from Day 0 to Day 112 (including Day 0 as baseline)

Secondary Outcomes (2)

• Participant self-assessment

  Day 112 (End of the study period)

• Eyelash specialist assessment

  Day 112 (End of the study)

Study Arms (2)

Group 1: Placebo control

PLACEBO COMPARATOR

Base formula without active ingredient

Other: Placebo control

Group 2: Experimental formula

EXPERIMENTAL

Base formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7).

Other: Experimental formula

Interventions

Placebo control OTHER

Placebo Control (Base Formula without active ingredients). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat application twice daily, in the morning and evening.

Group 1: Placebo control

Experimental formula OTHER

Base formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat this application twice daily, in the morning and evening.

Group 2: Experimental formula

Eligibility Criteria

• Age: 18 Years - 60 Years
• Gender Eligibility Details: Female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy female adults from the age of 18 to 60 years (inclusive).
• Having symptoms of alopecia, baldness, or self-identified with hair thinning.
• Absence of chronic diseases, major illnesses, or allergies.
• Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant

You may not qualify if:

• Currently taking any medication or using any eyelash care products.

Sponsors & Collaborators

• Hungkuang University: lead
• Schweitzer Biotech Company: collaborator

Study Sites (1)

Hungkuang University

Taichung, 433304, Taiwan

Location

MeSH Terms

Conditions

Skin Diseases

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Vice President

Study Record Dates

• First Submitted: November 27, 2025
• First Posted: December 9, 2025
• Study Start: November 1, 2025
• Primary Completion: May 1, 2026
• Study Completion: May 1, 2026
• Last Updated: December 9, 2025

Record last verified: 2025-11

Locations

TW (1)